Observational studyThe Journal of infectious diseases2025
Reduced Metformin Concentrations in Obese Women With Human Immunodeficiency Virus Treated With Dolutegravir.
Observational study in The Journal of infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Trust, but Verify: Translating Dosing Evidence to Understudied Populations in Low- and Middle-Income Countries.Clinical pharmacology and therapeutics · 2026Article
- Low metformin concentrations in obese people with HIV treated with dolutegravir.African journal of primary health care & family medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundObesity among women with human immunodeficiency virus (WWH) is nearly 2-fold higher than in men. Obesity is closely associated with dysglycemia, and frequently necessitates the coadministration of dolutegravir and metformin. A pharmacokinetic study in 15 nonobese healthy volunteers determined that dolutegravir increased metformin plasma exposure by 79%, prompting regulatory and guideline recommendations to limit metformin to 1000 mg/day when coadministered with dolutegravir. Obesity has been linked to lower metformin exposures, and our study aimed to verify the metformin pharmacokinetic exposure in the increasing population of obese WWH.
methodsWe conducted intensive plasma sampling in virally suppressed WWH receiving metformin extended-release 1000 mg once daily with concomitant dolutegravir 50 mg once daily. Dual-energy X-ray absorptiometry was performed to quantify body fat composition. Noncompartmental analysis of metformin and dolutegravir concentrations was performed, and our findings were compared to the reference study.
resultsWe enrolled 15 participants with a mean body mass index of 45.6 kg/m2. Metformin area under the concentration-time curve over the 24-hour dosing interval (AUC0-24) was 40.9% lower and dolutegravir AUC0-24 was 54.4% lower in obese WWH compared to the reference study. Metformin and dolutegravir clearance were 1.7- and 2.2-fold higher, respectively. Linear regression did not show associations between body fat composition and metformin or dolutegravir exposures.
conclusionsLimiting metformin to 1000 mg daily is likely to lead to underdosing in obese WWH on dolutegravir. Lower metformin exposure appears to be due to the reduced inhibitory effect of lower dolutegravir concentrations on metformin clearance and increased volume of distribution due to obesity. Our data support the revision of the current maximum dose restriction of metformin in the target population of obese WWH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.